U.S. regulators prioritize corporate-driven medical device approvals, sidelining systemic healthcare equity and long-term cost burdens

Indigenous healthcare systems globally prioritize preventive care, community-based interventions, and low-cost technologies over high-tech devices. The U.S. policy’s focus on 'breakthrough' devices aligns with Western biomedical reductionism, which often sidelines traditional knowledge and holistic healing practices. Indigenous communities, such as those in the Amazon or Pacific Islands, have long used plant-based and manual therapies that achieve outcomes comparable to Western devices at a fraction of the cost. This systemic bias reinforces colonial legacies in healthcare, where Western innovation is valorized while Indigenous solutions are marginalized.

The FDA’s 1976 Medical Device Amendments were a response to public outrage over unsafe devices like the Dalkon Shield, but industry lobbying has since eroded safety standards. The 'breakthrough device' pathway mirrors the 2012 FDA Safety and Innovation Act’s expedited approvals for drugs, which led to a 40% increase in post-market safety issues. Historically, such policies have been justified by appeals to 'innovation,' but often serve to accelerate corporate profits while shifting risks to patients and taxpayers. The current proposal risks repeating these patterns, particularly as Medicare’s financial sustainability becomes increasingly precarious.

Cross-culturally, the prioritization of high-tech medical devices reflects a Western biomedical paradigm that equates progress with technological intervention. In contrast, systems like Traditional Chinese Medicine (TCM) or African holistic health frameworks emphasize balance, prevention, and individualized care, which can reduce reliance on expensive devices. For instance, acupuncture and herbal medicine have been shown to manage chronic pain and inflammation without the need for surgical implants or imaging technologies. The U.S. model’s singular focus on devices ignores these alternatives, which are often more accessible and culturally resonant.

The scientific literature on medical device regulation highlights trade-offs between speed and safety, with expedited pathways linked to higher rates of recalls and adverse events. Studies show that devices approved through expedited pathways are 2-3 times more likely to require post-market surveillance or recalls compared to those approved through standard processes. The FDA’s own data indicates that 'breakthrough' designations have been granted to devices with limited clinical evidence, raising concerns about the rigor of pre-market evaluations. Additionally, the long-term cost-effectiveness of these devices is rarely assessed, despite Medicare’s role in bearing the financial burden.

Artistic and spiritual traditions often frame health as a balance of physical, emotional, and environmental factors, rather than a series of technological interventions. For example, Ayurveda views illness as a disruption in the body’s energy systems, which can be addressed through diet, meditation, and herbal remedies—none of which require FDA-approved devices. Similarly, many Indigenous cultures see health as inseparable from land, community, and spiritual well-being, a perspective that challenges the commodification of medical technology. The U.S. healthcare system’s focus on devices reflects a mechanistic worldview that divorces health from its broader ecological and social contexts.

If this policy is implemented, Medicare’s long-term financial strain could worsen, with projections suggesting a 15-20% increase in device-related spending over the next decade. The focus on breakthrough devices may also divert resources from preventive care and primary care infrastructure, exacerbating workforce shortages and geographic disparities. Future scenarios could include a two-tiered system where wealthy patients access cutting-edge devices while marginalized communities rely on underfunded public health systems. Conversely, if paired with investments in community-based care and comparative effectiveness research, this policy could be reoriented toward equitable innovation.

Marginalized communities—including Black, Indigenous, low-income, and rural populations—are disproportionately excluded from the benefits of 'breakthrough' devices due to cost, geographic barriers, and lack of insurance coverage. These groups are also more likely to experience adverse outcomes from medical devices, as seen in the high rates of complications from pelvic mesh implants in women of color. The policy’s framing ignores the structural racism and classism embedded in healthcare access, instead positioning innovation as a universal good. Additionally, the voices of patients who cannot afford these devices or whose conditions are deemed 'non-innovative' are entirely absent from the narrative.